An open-label study to estimate the effect of steady-state erythromycin on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban in subjects with renal impairment and normal renal function

Two previously conducted rivaroxaban studies showed that, separately, renal impairment (RI) and concomitant administration of erythromycin (P-glycoprotein and moderate cytochrome P450 3A4 [CYP3A4] inhibitor) can result in increases in rivaroxaban exposure. However, these studies did not assess the p...

Descripción completa

Detalles Bibliográficos
Autores principales: Moore, Kenneth T, Vaidyanathan, Seema, Natarajan, Jaya, Ariyawansa, Jay, Haskell, Lloyd, Turner, Kenneth C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2014
Materias:
Drug-Drug Interactions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4241044/
https://www.ncbi.nlm.nih.gov/pubmed/24964176
http://dx.doi.org/10.1002/jcph.352

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4241044/
https://www.ncbi.nlm.nih.gov/pubmed/24964176
http://dx.doi.org/10.1002/jcph.352

Ejemplares similares